Escalation strategies for combination therapy Phase I trials
Phase I clinical trials aim to identify a maximum tolerated dose (MTD), the highest possible dose that does not cause an unacceptable amount of toxicity in the patients. In trials of combination therapies, however, many different dose combinations may have a similar probability of causing a dose-lim...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
John Wiley & Sons, Ltd
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573644/ |